Section Arrow
IVVD.NASDAQ
- Invivyd
Quotes are at least 15-min delayed:2026/05/15 19:40 EDT
After Hours
Last
 1.22
+0.01 (+0.83%)
Bid
1.2
Ask
1.22
High 1.24 
Low 1.2 
Volume 17.85K 
Regular Hours (Closed)
Last
 1.21
+0.05 (+4.31%)
Day High 
1.34 
Prev. Close
1.16 
1-M High
1.8 
Volume 
7.27M 
Bid
1.2
Ask
1.22
Day Low
1.14 
Open
1.16 
1-M Low
1.11 
Market Cap 
328.05M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.44 
20-SMA 1.48 
50-SMA 1.53 
52-W High 3.0699 
52-W Low 0.483 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.30/-0.26
Enterprise Value
329.23M
Balance Sheet
Book Value Per Share
0.85
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
53.43M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HCWBHCW Biologics Inc1.22+0.883+262.02%-- 
After Hours 1.07 -0.15 -12.30%
ADTXAditxt Inc.0.0632-0.0036-5.39%-- 
After Hours 0.054121 -0.009079 -14.37%
RXRXRecursion Pharmaceuticals2.93-0.11-3.62%-- 
After Hours 2.9287 -0.0013 -0.04%
GERNGeron Corp1.29-0.11-7.86%-- 
After Hours 1.31 +0.02 +1.55%
NTLAIntellia Therapeutics13.67+0.58+4.43%-- 
After Hours 13.5 -0.17 -1.24%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.